Urban One (NASDAQ:UONEK) Bolsa

Urban One

Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.

Urban One Inc

Earnings

News

GRMN

Garmin Q1 Gross Margin 57.6% vs 58.1% YoY

SPWR

SunPower Formerly Complete Solaria Reports Q1 Revenues Of $88.674M, Company Finished Q1 With $14M In Cash Vs. $13.3M In Q4

First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.03 by 200 percent. This is a 350 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $71.40 million which beat the analyst consensus estimate of $64.19 million by 11.24 percent. This is a 39.81 percent increase over sales of $51.07 million the same period last year.

Earnings Beats

FFWM

First Foundation Q1 Adj. EPS $0.09 Beats $0.03 Estimate, Sales $71.40M Beat $64.19M Estimate

Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 70.37 percent decrease over losses of $(0.27) per share from the same period last year.

Earnings Misses

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and maintains $2500 price target.

Price Target

Reiteration

Analyst Ratings

FICO

Needham Reiterates Buy on Fair Isaac, Maintains $2500 Price Target

DTCK

Davis Commodities Forms Strategic Joint Venture With Malaysian Agri-Processor To Tap ASEAN FTA Benefits And Secure Key Market Access

EXTR

Extreme Networks Q3 2025 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $284.50M Beat $280.32M Estimate

USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company), today announced that it has entered into a securities purchase agreement with a new fundamental institutional investor to raise $75 million of equity capital via a private investment in public equity ("PIPE"). The Company intends to use the proceeds from the offering to fund capital expenditures for its magnet manufacturing facility in Stillwater, Oklahoma, as well as for working capital and operating expenses.
Under the terms of the securities purchase agreement, the Company will issue, for an aggregate purchase price of $75 million, an aggregate of approximately 8.55 million shares of common stock (the Issued Shares), pre-funded warrants to purchase an aggregate of approximately 2.16 million shares of common stock (the shares underlying the Pre-Funded Warrants, together with the Issued Shares, "the Aggregate Shares") and warrants (the PIPE Warrants) to purchase shares of common stock, in an amount equal to 100% of the Aggregate Shares at a strike price of $7.00 per share, with an expiry date of 6-years from the issue date of the PIPE Warrants. The Shares and the PIPE Warrant Shares are entitled to customary resale registration rights.
 &nbsp;

USAR

USA Rare Earth Enters Into Securities Purchase Agreement With New Fundamental Institutional Investor To Raise $75M Of Equity Capital Via PIPE

TLRY

Tilray Brands' 10 Barrel Brewing Unveils NA Apocalypse IPA, Offering Bold, Hop-Driven Flavor Without The Alcohol

ETSY

Etsy Q1 2025 Adj. EPS $0.46 Misses $0.49 Estimate, Sales $651.18M Beat $642.67M Estimate

Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. This is a 51.85 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $2.35 billion which beat the analyst consensus estimate of $2.30 billion by 2.33 percent. This is a 14.00 percent decrease over sales of $2.73 billion the same period last year.

Dana Q1 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $2.35B Beat $2.30B Estimate

Leerink Partners analyst Puneet Souda downgrades NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Outperform to Market Perform and lowers the price target from $25 to $9.

Downgrades

Leerink Partners Downgrades NeoGenomics to Market Perform, Lowers Price Target to $9

HC Wainwright &amp; Co. analyst Yi Chen reiterates LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and maintains $14 price target.

LFMD

HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $14 Price Target

Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) affirms FY2025 Adj EPS guidance from $4.40-$4.60 to $4.40-$4.60 vs $4.49 analyst estimate..

Guidance

Spire Affirms FY2025 Adj EPS Guidance of $4.40-$4.60 vs $4.49 Est

<ul>
<li>Amylyx expects completion of recruitment for the LUCIDITY trial in 2025, with topline data in first half of 2026</li>
<li>Pivotal Phase 3 LUCIDITY trial evaluating avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation; FDA-agreed-upon primary outcome of reduction in hypoglycemic events</li>
<li>Avexitide has been previously evaluated in five post-bariatric hypoglycemia (PBH) clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant reductions in hypoglycemic events</li>
<li>The Company continues to expect cash runway through the end of 2026</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54246224&amp;newsitemid=20250429337166&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=4a42d2ccab20c0ba32567d801f80a9bc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that the first participant has been dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH).

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Amylyx Pharma Announces First Participant Dosed In Pivotal Phase 3 LUCIDITY Clinical Trial Of Avexitide For Treatment Of Post-bariatric Hypoglycemia

XPRO

Expro Group Holdings Says 'Consistent with our fourth quarter earnings call, our view remains that we will continue to make progress in 2025 toward our medium-term target of mid-20s Adjusted EBITDA margin, notwithstanding near-term uncertainty related to tariffs, additional OPEC+ supply, and a range of geopolitical risks'

<ul>
<li>Statistically significant efficacy in biomarker subgroup analyses was observed:</li>
<li>&nbsp;
<ul>
<li>78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup</li>
<li>61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup</li>
<li>90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score (CPS) subgroup</li>
</ul>
</li>
<li>The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study</li>
</ul>

PPBT

Purple Biotech's CM24 Shows Up To 90% Reduction In Death Risk In Pancreatic Cancer Patients, Biomarker Insights To Drive Next Phase 2b Study

Stock Split

LITM

Snow Lake Resources Announces 1-for-13 Reverse Stock Split, Will Become Effective May 2

Martin Marietta Sees FY25 Revenue Of $6.830B - $7.230B Vs. $7.021B Est.

Expro Gr Hldgs Sees Q2 Sales $400.000M-$410.000M vs $430.43M Est

Entertainment

Press Releases

General

DON LEMON, JOY-ANN REID, TARANA BURKE, DR. CORNEL WEST AND OTHER HIGH-PROFILE VOICES WEIGH IN ON THE 2024 ELECTION & VOTING RIGHTS HISTORY IN NEWSONE SERIES 'THE BLACK BALLOT'

Small Cap

Urban One, Inc. Second Quarter 2024 Results Conference Call

URBAN ONE, INC. REPORTS SECOND QUARTER 2024 RESULTS

Urban One, Inc. Third Quarter 2024 Results Conference Call

URBAN ONE TO EXPAND SPANISH LANGUAGE PROGRAMMING WITH LOCAL MANAGEMENT AGREEMENT WITH LA MEGA MEDIA AND LAZO MEDIA; CLAUDIA DELEON APPOINTED VP, GENERAL MANAGER OF ITS CLEVELAND MARKET AND HEAD OF SPANISH BROADCAST OPERATIONS

Comments

Urban One

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL